We audited the marketing at PhaseV
AI platform accelerating clinical trial design and portfolio decisions
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
Enterprise biotech buyers rarely search for trial optimization tools, making organic discovery difficult for niche B2B SaaS
Series A company at 53 headcount likely lacks dedicated demand gen, relying on founder networks and early adopter referrals
Clinical development buyers consume specialized content (regulatory, statistical, operational) that generic B2B content misses
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiHere's Where You Stand
Series A biotech SaaS with strong funding but minimal visible marketing infrastructure beyond LinkedIn presence
Trial optimization and ClinOps terms have low search volume but high intent. No evidence of ranking for trial design, cost reduction, or enrollment keywords targeting sponsors and CROs
MH-1: SEO agent targets clinical development keywords (trial protocol optimization, site selection software, enrollment forecasting) with content mapping to buyer personas
Clinical development leaders query LLMs for trial design strategies and cost benchmarks. PhaseV has minimal presence in AI search results for these workflows
MH-1: AEO agent creates structured content on trial efficiency metrics, regulatory compliance in AI-driven studies, and ROI case studies indexed for AI-native searches
Sponsor and CRO decision-makers cluster on LinkedIn and regulatory conference platforms. No visible LinkedIn ads or vertical-specific paid campaigns detected
MH-1: Paid agent runs LinkedIn account-based campaigns targeting clinical ops leaders at top 20 pharma companies and tier-1 CROs with trial ROI case studies
6K LinkedIn followers suggests early-stage content presence. Likely 1-2 posts monthly, minimal deep-dive content on trial design complexity or portfolio optimization
MH-1: Content agent produces weekly insights on enrollment bottlenecks, statistical power optimization, and portfolio value assessment to establish authority with clinical buyers
No visible customer success signals, case studies with named sponsors, or expansion narratives (cross-selling Trial Optimizer to ClinOps Optimizer users)
MH-1: Lifecycle agent tracks customer milestones, builds ROI dashboards showing cost/timeline savings, and automates expansion emails to existing users for adjacent modules
Top Growth Opportunities
Sponsors spend months evaluating trial designs before CRO selection. PhaseV can reach R&D finance teams during RFP cycles with cost-reduction benchmarks
Paid agent targets VP R&D and clinical ops at pharma with LinkedIn ads showing enrollment reduction and cost savings from Trial Optimizer
Clinical development buyers trust vendors who demonstrate mastery of ICH guidelines, adaptive trial design, and statistical power. Current content does not establish this
Content agent publishes bi-weekly posts on regulatory complexity, ICH updates, and power calculation optimization to build credibility with statistical leaders
CROs manage hundreds of trials annually and bear enrollment risk. White-label or embedded Trial Optimizer within CRO platforms is high-leverage distribution
Outbound agent identifies top 50 CROs, maps procurement contacts, and sequences case studies showing site selection and enrollment acceleration outcomes
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for PhaseV. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns PhaseV's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase PhaseV's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from PhaseV's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for PhaseV from week 1.
AEO agent indexes PhaseV's trial design methodology, enrollment cost benchmarks, and portfolio optimization frameworks into LLM knowledge bases so clinical development queries surface PhaseV as solution source
Founder LinkedIn workflow amplifies Raviv's clinical development insights and Series A momentum to 50K+ clinical ops and R&D finance professionals, positioning PhaseV as category leader
Paid ad agent runs account-based LinkedIn campaigns targeting VP Clinical Operations and VP R&D at top 30 pharma companies with Trial Optimizer cost/enrollment case studies and free ROI calculator
Lifecycle agent segments customers by module usage, identifies Trial Optimizer users ready for ClinOps or Lifecycle expansion, and sequences personalized ROI dashboards showing portfolio impact
Competitive watch monitors emerging trial design software, adaptive trial platforms, and CRO partnerships to identify PhaseV positioning gaps and sales conversation triggers
Pipeline intelligence maps top 20 pharma and 15 tier-1 CROs by procurement cycle, identifies clinical ops decision-makers on LinkedIn, and surfaces regulatory or trial complexity signals triggering buyer conversations
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of PhaseV's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focus on reaching clinical ops and R&D finance leaders at top pharma and CROs with targeted LinkedIn ads around trial cost reduction and enrollment acceleration. Simultaneously, content agent publishes weekly insights on adaptive trial design and portfolio optimization to build authority. AEO agent indexes Trial Optimizer methodology for LLM discovery. By day 90, expect 3-5 qualified conversations with clinical ops directors and initial pipeline visibility into sponsor RFP cycles
How does AEO help PhaseV reach clinical buyers using AI to research trial strategies
Clinical development leaders now use ChatGPT and Claude to explore trial optimization strategies, enrollment cost benchmarks, and regulatory complexity. AEO optimizes PhaseV's content, case studies, and methodology frameworks for LLM indexing so when buyers ask for AI-driven trial design approaches, PhaseV's solutions appear as credible options in AI search results
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for PhaseV specifically.
How is this page personalized for PhaseV?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of PhaseV's current marketing. This is a live demo of MH-1's capabilities.
Scale clinical buyer awareness while your Trial Optimizer solves 40% enrollment and cost problems
The system gets smarter every cycle. Let's talk about building it for PhaseV.
Book a Strategy CallMonth-to-month. Cancel anytime.